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ATGGCTGCCGAGGATGTGGTGGCGACTGGCGCCGACCCAAGCG 
M A A E D V V A T G A D P S D 
ATCTGGAGAGCGGCGGGCTGCTGCATGAGATTTTCACGTCGCC 
L E S G G L L H E I F T S P 
GCTCAACCTGCTGCTGCTTGGCCTCTGCATCTTCCTGCTCTAC 
L N L L L L G L C I F L L Y 
AAGATCGTGCGCGGGGACCAGCCGGCGGCCAGCGGCGACAGCG 
K I V R G D Q P A A S G D S D 
ACGACGACGAGCCGCCCCCTCTGCCCCGCCTCAAGCGGCGCGAC 
D D E P P P L P R L K R R D 
TTCACCCCCGCCGAGCTGCGGCGCTTCGACGGCGTCCAGGACCC 
F T P A E L R R F D G V Q D P 
GCGCATACTCATGGCCATCAACGGCAAGGTGTTCGATGTGACCA 
R I L M A I N G K V F D V T K 
AAGGCCGCAAATTCTACGGGCCCGAGGGGCCGTATGGGGTCTTT 
G R K F Y G P E G P Y G V F 
GCTGGAAGAGATGCATCCAGGGGCCTTGCCACATTT'I'GCCTGGA 
A G R A S R G L A T F C L D 
TAAGGAAGCACTGAAGGATGAGTACGATGACCTTTCTGACCTCA 
K E A L K D E Y D D L S D L T 
CTGCTGCCCAGCAGGAGACTCTGAGTGACTGGGAGTCTCAGTTC 
A A Q Q E T L S D W E S Q F 
ACTTTCAAGTATCATCACGTGGGCAAACTGCTGAAGGAGGGGGA 
T F K Y H H V G K L L K E G E 
GGAGCCCACTGTGTACTCAGATGAGGAAGAACCAAAAGATGAGA 
E P T V Y S D E E ‘E P K D E S 
GTGCCCGGAAAAATGATTAAAGCATTCAGTGGAAGTATATCTAT 
A R K N D * 
TTTTGTA 
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HPR6 MUTANTS AND USES THEREOF 
FIELD OF THE INVENTION 
The invention relates to Hpr6 mutants and their use. In 
particular, the present invention relates to the use of the 
human Hpr6 protein as a target for development of anti 
cancer drugs, as Well as adenoviral vectors encoding a 
mutant Hpr6 for use in anti-cancer therapy. 
BACKGROUND OF THE INVENTION 
Therapeutic treatments for solid tumors usually include a 
combination of DNA damaging agents, including a class of 
compounds that are metabolized by the CYP3A4 protein. 
These DNA damaging agents include topoisomerase inhibi 
tors, and doxorubicin or adriamycin, Which is an anthracy 
cline antibiotic that is frequently used in combination With 
other drugs for treating breast cancer. Doxorubicin acts 
through multiple mechanisms that include intercalating 
Within DNA, binding to topoisomerase II, and generating 
reactive oxygen species. The effectiveness of doxorubicin 
or topoisomerase inhibitor-based chemotherapy is limited 
by drug resistance. For example, doxorubicin resistance can 
emerge through alterations of proteins regulating the avail 
ability, activation, or inactivation of the drug, through 
changes in topoisomerase II, or through changes in path 
Ways mediating DNA repair and apoptosis. The proteins that 
cause chemotherapeutic resistance are potential therapeutic 
targets for cancer, and inhibiting these proteins could lead to 
improved effectiveness of doxorubicin and other compounds 
that are metabolized by Cyp3A4. 
Hpr6 is a member of the heme-1 domain family of 
proteins, Which includes the human Hpr6 and Dg6 proteins, 
the rodent 25-Dx and IZAg proteins, and the budding yeast 
Dap1p protein. The Hpr6/25-Dx/IZAg/Dap1p proteins are 
relatively small (approximately 25 kDa) and are composed 
largely of a central heme-1 domain that shares homology 
With cytochrome b5. Like cytochrome b5, the IZAg protein 
binds to heme. Dap 1 p damage resistance protein, 7) Was 
previously identi?ed in Saccharomyces cerevisiae, a model 
organism for studying chemotherapeutic resistance. Yeast 
mutants lacking Dap 1 p exhibit extreme sensitivity to a 
DNA alkylating agent and are moderately sensitive to 
hydroxyurea and radiation (Hand R A et al., Eukaryolic Cell 
2003; 2: 121-32). 
Thus, drugs that target the Hpr6 protein are potentially 
useful for treating cancer. Drug resistance is one of the 
primary causes underlying failure of treatment for cancer, 
and there is a profound need to screen for inhibitors of the 
Hpr6 pathWay. 
SUMMARY OF THE INVENTION 
In one aspect of the invention there is provided a mutant 
Hpr6 polypeptide (Hpr6-mut) consisting of the amino acid 
sequence SEQ ID NO:1. 
In another aspect of the invention there is provided an 
isolated nucleic acid encoding Hpr6-mut. 
In another aspect of the invention there is provided a 
vector encoding Hpr6-mut. In preferred embodiments, the 
vector is an adenoviral vector, most preferably a replication 
de?cient adenoviral vector; or a plasmid. 
In a further aspect of the invention there is provided a 
method for treating a non-sarcoma tumor comprising admin 
istering to a patient an anti-cancer agent that is metaboliZed 
by Cyp3A4 and a replication defective adenovirus vector 
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2 
comprising a nucleotide sequence encoding Hpr6-mut, 
Wherein the Hpr6-mut is expressed in said tumor. In a 
preferred embodiment the anti-cancer agent is doxorubicin. 
In another aspect of the invention there is provided a 
method of enhancing the effect of a Cyp3A4 metaboliZable 
anti-cancer agent in a non-sarcoma tumor of a patient 
comprising administering to the patient a replication defec 
tive adenovirus vector comprising a nucleotide sequence 
encoding Hpr6-mut; and administering the Cyp3A4 metabo 
liZable anti-cancer agent to the patient, Wherein the Hpr6 
mut is expressed in said tumor. In a preferred embodiment 
the anti-cancer therapeutic agent is administered Within 
about one to about tWenty four hours of administration of the 
adenoviral vector. 
In another aspect of the invention there is a method of 
screening test agents comprising contacting cells that over 
express Hpr6 With the test agents and doxorubicin or other 
Cyp3A4 metaboliZable anti-cancer agent; Wherein test 
agents that result in enhanced cell death compared to Hpr6 
overexpressing cells that are contacted With only the 
Cyp3A4 metaboliZable anti-cancer agent are identi?ed as 
anti-Hpr6 agents. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 shoWs that Hpr6 is expressed in breast cancer cell 
lines and is induced by doxorubicin. 1A: Western blot 
analysis shoWing expression of Hpr6 (top panel) and tubulin 
(bottom panel) in the cell lines BT549 (lane 1), MCF-7 (lane 
2), HCT-100 (lane 3), MDA-MB-231 (lane 4), MDA-MB 
435 (lane 5), and HeLa (lane 6). Hpr6 migrates as a 27 kDa 
protein. The position of molecular Weight markers is indi 
cated to the left. 1B: Hpr 6 expression is induced after 
treatment With doxorubicin and camptothecin. MDA-MB 
231 cells Were untreated (upper panel, lane 1), treated With 
0.5 or uM doxorubicin (upper panel, lanes 2 and 3), or 0.25 
1 um camptothecin (upper panel, lane 4) for 3 days, and the 
expression of Hpr6 Was analyZed by Western blot. Hpr6 
expression Was elevated sharply by exposure to the tWo 
drugs as indicated by the fold increase indicated beloW the 
upper panel. Tubulin is included as a control for equal 
protein loading (loWer panel). 
FIG. 2. The Ad-Hpr6-mut adenovirus directs expression 
of an inactive form of Hpr6. 2A: Puri?cation of GST-Hpr6 
(lane 1) and GST-Hpr6-mut (lane 2) fusion proteins. Pro 
teins Were puri?ed using glutathione-agarose and analyZed 
by SDS-PAGE electrophoresis. 2B: Heme binding by Hpr6 
(left column) but not Hpr6-mut (right column). SolubiliZed 
proteins Were analyZed for absorbance at 400 nm, and 
measurements Were performed in triplicate. 2C: Western blot 
analysis of MDA-MB-231 cells infected With 500, 1000, or 
2000 pfu/cell of Ad-Hpr6-mut (lanes 1-3) or 2000 pfu/cell of 
Ad-LacZ (lane 4). Hpr6 expression Was visualiZed With an 
antibody to the HA epitope tag. D. The Hpr6-mut protein is 
overexpressed compared to endogenous Hpr6 folloWing 
Ad-Hpr6-mut infection. MDA-MB 231 cells Were infected 
With Ad-LacZ (lane 1) or Ad-Hpr6-mut (lane 2) and ana 
lyZed by Western blots probed for HA (top panel), Hpr6 
(middle panel), or tubulin (bottom panel). The positions of 
the exogenous Hpr6-mut and endogenous Hpr6 protein are 
indicated in the center panel (top and bottom, respectively). 
FIG. 3. Ad-Hpr6-mut acts synergistically With doxorubi 
cin to induce cell death. 3A: graph shoWing viability of 
MDA-MB-231 cells infected either Ad-LacZ (solid line) or 
Ad-Hpr6-mut (dashed line), combined With increasing con 
centrations of doxorubicin Qi axis). Viability Was measured 
by MTT assay. 3B: graph shoWing viability of MDA-MB 
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231 cells infected either Ad-LacZ (solid line) or Ad-Hpr6 
mut (dashed line), combined With 0-41 uM doxorubicin Qi 
axis). Viability Was measured by trypan blue assay. 3C: 
graph showing viability of MDA-MB-231 cells treated With 
1 uM doxorubicin combined With increasing doses of either 
Ad-LacZ (solid line) or Ad-Hpr6-mut (dashed line). Viabil 
ity Was measured by MTT assay. D, graph shoWing viability 
of MDA-MB-231 cells infected either Ad-LacZ (solid line) 
or Ad-Hpr6-mut (dashed line), combined With increasing 
concentrations of camptothecin Qi axis). For all of the 
assays, error bars represent the standard deviations of trip 
licate measurements and the results shoWn are representative 
of at least three independent experiments. 
FIG. 4. Hpr6-mut induces cell death, but does not alter 
doxorubicin localization. 4A: Morphology of MDA-MB 
231 cells infected With Ad-LacZ (left panel) or Ad-Hpr6-mut 
(right panel) and treated With 1 uM doxorubicin for 72 
hours. Ad-Hpr6-mut-infected, doxorubicin-treated cells 
generally had a rounded or necrotic morphology. 4B: Hpr6 
mut does not alter the localiZation or short-term accumula 
tion of doxorubicin. MDA-MB-231 cells Were infected With 
either Ad-LacZ (left panels) or Ad-Hpr6-mut (right panels) 
and treated With 10 uM doxorubicin for 1 hour. Cells Were 
then ?xed and visualiZed using bright-?eld microscopy (top 
panels) or ?uorescence (bottom panels). In both groups of 
infected cells, doxorubicin accumulated in the nucleus to 
similar extents. These results Were con?rmed by F ACS 
analysis (data not shoWn). 
FIG. 5. Hpr6 overexpression in clinical breast tumor 
samples. 5A: Western blot analysis of Hpr6 expression in 
paired normal (N, odd lanes) and tumor (T, even lanes) 
samples from the same patients (lanes 1-6). Hpr6 Was 
overexpressed in tumors from patients 1 and 3. B, Hpr6 
overexpression in unmatched breast tumor samples. Hpr6 
expression Was high in tumors from 4 separate patients 
(lanes 1, 3, 5, and 6). 
FIG. 6. Hpr6 localiZes to the perinuclear region in MCF-7 
breast cancer cells. MCF-7 cells Were transfected With the 
control plasmid pBK-CMV (panels 1 and 2) or the Hpr6 
expression plasmid pBK-Hpr6 (panels 3-6) and isolates 
Were selected that stably expressed Hpr6 (ref. 13). Cells 
Were plated on 4-Well chamber slides and analyZed by bright 
?eld microscopy (panels 1, 3, and 5) or by immuno?uores 
cence after staining With an antibody directed to HA (panels 
2, 4, and 6). Panels 1-4are at 100x resolution, While panels 
5 and 6 are at 400x. 
FIG. 7. The amino acid sequence (SEQ ID NO:1) and 
corresponding nucleotide sequence (SEQ ID NO:2) of Hpr6 
mut are shoWn. The heme binding region (SEQ ID NO:3) is 
highlighted by underlining. In Hpr6-mut, the aspartic acid 
(D) at amino acid position 120 Within the heme binding 
region is mutated to glycine (G), Which inactivates the 
protein (SEQ ID NO:11). 
DETAILED DESCRIPTION OF THE 
INVENTION 
The Hpr6 protein (also referred to as Hpr6.6, MAPR, and 
PGRMC-l) is a heme1 domain protein that is believed to 
regulate the turnover of cellular metabolites. It is shoWn 
herein that Hpr6 is overexpressed in cancer cells, such as 
human breast, colon and thyroid tumors (but not in sarco 
mas), and tumor-derived cell lines and functions therein to 
protect these cells from cell death. 
The Hpr6-related proteins are proposed to play a role in 
metabolism and cancer for the folloWing reasons: (a) the rat 
25-Dx protein and its porcine homologues are microsomal 
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proteins that bind to progesterone and regulate its metabo 
lism; (b) the rat 25-Dx protein is up-regulated in liver tumors 
induced by dioxin; and (c) breast cancer cells engineered to 
overexpress Hpr6 are hypersensitive to oxidative damage 
(Hand R A and Craven R J. Journal of Cellular Biochemistry 
2003; 90: 534-47). HoWever, fundamental questions such as 
the localiZation of Hpr6, its expression in cancer, and its 
biochemical activities have not been previously reported. 
To test the role of Hpr6 in resistance to chemotherapeutic 
agents, an efficient means of inhibiting Hpr6 in tumors Was 
developed, and the ability of cells With inhibited Hpr6 
function to respond to damage Was tested. Breast cancer 
cells Were infected With an adenovirus bearing a dominant 
negative mutant of Hpr6 and treated With doxorubicin and 
other anti-cancer agents. It is shoWn herein that expression 
of mutant Hpr6 triggers cell death folloWing anti-cancer 
agent therapy, such as for example doxorubicin therapy or 
other anti-cancer agents that are metaboliZed by Cyp3A4. 
This suggests that Hpr6 might function in tumors to promote 
chemotherapeutic resistance. It is also shoWn that Hpr6 is 
overexpressed in approximately half of clinical breast tumor 
samples. Together, these ?ndings indicate that Hpr6 medi 
ates resistance to chemotherapeutic agents in cancer cells 
and is a target for therapeutic intervention. 
The studies disclosed herein demonstrate that; (i) Hpr6 is 
overexpressed in breast tumors; and (ii) Hpr6 binds to heme 
and localiZes to the endoplasmic reticulum; and (iii) an 
inactive mutant of the Hpr6 protein Which inhibits Hpr6 
heme binding sensitiZes metastatic cancer cells to chemo 
therapeutic agents, in particular Cyp3A4 metaboliZable 
compounds. The role of Hpr6 in cancer has not been 
examined previously, and these results demonstrate that 
Hpr6 function in normal cells is corrupted in tumors cells to 
yield improved resistance to chemotherapeutic agents, e.g., 
etoposide (ETP), adriamycin (doxorubicin: DOX), taxol, 
paclitaxol and irinotecan (CPT-ll) and other Cyp3A4 
metaboliZable anti-cancer agents for example. 
There is a precedent for Hpr6 homologues directing 
resistance to DNA damaging agents, because the Hpr6 yeast 
homologue is required for resistance to the methylating 
agent MMS and plays a minor role in resistance to radiation 
(Hand R A et al. Eukaryolic Cell 2003; 2: 121-32). There is 
also a precedent for Hpr6 homologues regulating metabo 
lism, because the rodent Hpr6 homologue increases 
hydroxylation of progesterone, a key step in its metabolism 
(Min L et al. Mol Cell Endocrin 2004; 215: 143-8). Our 
results suggest that the effects of Hpr6 on xenobiotic com 
pounds are fairly speci?c to compounds that are metaboliZed 
by Cyp3A4. A mutant of Hpr6, referred to herein as Hpr6 
mut, inhibited survival folloWing doxorubicin treatment, but 
had no effect on survival from treatment With mechlore 
thamine. This Was someWhat surprising given that yeast 
lacking the Hpr6 homologue, Dap1p, are extremely sensitive 
to alkylating agent MMS (Hand R A et al. Eukaryolic Cell 
2003; 2: 121-32), but are relatively insensitive to doxoru 
bicin (Craven, unpublished observations). Thus, it appears 
that the speci?cities of Dap1p and Hpr6 dilfer, perhaps due 
to species differences. 
Hpr6 expression is induced by doxorubicin and camp 
tothecin, and Hpr6 induction parallels the activity of the 
Ad-Hpr6-mut adenovirus to various drugs, including doxo 
rubicin, camptothecin and etoposide, for example. Microar 
ray analyses have identi?ed a number of proteins that are 
induced by doxorubicin, including the DNA repair gene 
XRCCl, the Fms-related tyrosine kinase, and the 268 pro 
teosome regulatory sub-unit 4 (Kudoh et al. Cancer Res 
2000; 60: 4161-4166) A similar analysis in patients treated 
US 7,342,100 B2 
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With doxorubicin revealed similar changes in DNA repair 
genes, protein kinases, members of the proteosome pathway 
(Sotiriou et al. Breast Cancer Res 2002; 4: R3-11), although 
the speci?c genes di?cered from those identi?ed previously. 
Hpr6 (sometimes listed in databases as “PGRMCI” for 
progesterone receptor membrane component 1) Was not 
present on early microarrays, perhaps due to the high G-C 
content in the 5' region of the gene. Our results suggest that 
Hpr6 is induced as a part of a global response to neutraliZe 
topoisomerase inhibitor chemotherapeutic agents such as 
doxorubicin or resist cell death. It is shoWn herein, hoWever, 
that overexpression of the Hpr6-mut protein overcomes this 
response. 
The role for Hpr6 in providing resistance to Cyp3A4 
metaboliZable anti-cancer agents is consistent With its local 
iZation to the perinuclear region, Which is also the site for 
numerous cytochrome P450 proteins and drug metaboliZing 
proteins (Rieger et al. Cancer Res 2004; 64: 2357-64). In 
addition, doxorubicin accumulates in the perinuclear region 
in drug-resistant cell lines (Rajagopal et al. Mal Biai Cel/ 
2003; 14: 3389-99), presumably sequestering the drug from 
its nuclear site of action. Interestingly, cytochrome b5, the 
prototype heme-1 domain protein and a relative of Hpr6, 
localiZes to the endoplasmic reticulum (D’Arrigo et al. J 
Biai Chern 1993; 268: 2802-8) as does the heme metabo 
liZing protein heme oxygenase (Volti et al. Biachem and 
Biophys Res C0mm 2004 315: 517-524). The perinuclear 
staining pattern for Hpr6 resembles that reported for rodent 
homologues of Hpr6 in liver, While Hpr6 homologues have 
an additional membrane component in neuronal cells. 
Our results suggest that Hpr6 resides in the endoplasmic 
reticulum, Where it binds to heme and regulates resistance to 
anti-cancer agents. It is proposed that Hpr6 up-regulates the 
activity of proteins that metaboliZe chemotherapeutic agents 
such as doxorubicin, Which includes CYP3A4 or aldoke 
toreductase and that Hpr6-mut blocks this function. There is 
a precedent for Hpr6 homologues acting to promote CYP 
protein function. The rodent Hpr6 homologue, IZAg, 
increases CYP activity for 21-hydroxylation of progester 
one. Furthermore, the yeast Dap1p protein targets the pro 
tein Cyp51 (also knoWn as Ergllp), a highly conserved P450 
protein. Altemately, Hpr6 could regulate the activity of an 
aldoketoreductase (Peltoketo et al. J Mal Endocrin 1999; 23: 
1-11) Which reduces a ketone group at the C-13 position of 
doxorubicin. Through either mechanism, Hpr6 Would ulti 
mately drive the metabolism of therapeutic agents such as 
doxorubicin, and disruption of Hpr6 function With the Hpr6 
mut protein Would lead to cell death. 
The structural basis through Which Hpr6-mut disrupts 
Hpr6 function is unknown. One likely mechanism for Hpr6 
mut is competition With endogenous Hpr6 for binding to 
substrates and associated proteins. HoWever, there is evi 
dence that Hpr6 homologues function as a covalently bound 
dimer. Thus, Hpr6-mut could bind directly to Wild-type 
Hpr6, forming an inactive complex. Inactive homodimer 
formation is a common mechanism among dominant-nega 
tive mutants (Rishi et al. JBiai Chern 2004; 279: 11863-74; 
and Zhu et al. Mal Cell Biai 2004; 24: 2673-81), including 
drug resistance proteins (Kage et al. J Cancer 2002; 97: 
626-30) and cytochrome proteins (Curry et al. Genomics 
2004; 83: 425-38). HoWever, covalently bound dimers 
betWeen endogenous Hpr6 and Hpr6-mut Would have been 
detected on Western blots of infected cells (such as those in 
FIG. 2), and these bands Were not observed. 
Thus, Hpr6 appears to function in protecting tumor cells 
from anti-cancer agents that are metaboliZable by Cyp3A4. 
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In normal tissues, Hpr6 is highly expressed in liver and 
kidney (Gerdes et al. Biol Chem 1998; 379: 907-11), tissues 
that are directly exposed to compounds taken up by the 
digestive tract and Which express proteins that neutraliZe 
these compounds, such as P450 proteins (Watkins et al. Pr0c 
NallAcad Sci 1985; 82: 6310-4; and Phillips et al. Pr0c Natl 
Acad Sci 1985; 82: 983-987). 
When overexpressed in non-sarcoma tumors, such as 
breast tumor, lung tumors, ovarian tumors, colon tumors or 
thyroid tumors, for example, Hpr6 protects tumor cells from 
Cyp3A4 mataboliZable compounds, such as doxorubicin, 
etoposide and camptothecin providing resistance to this 
class of chemotherapeutic drugs. Furthermore, inhibiting 
Hpr6 increases the ability of chemotherapeutic drugs to kill 
cancer cells, Which makes Hpr6 a target for intervention in 
cancer therapy. 
Hpr6 is overexpressed in colon and thyroid tumors (but 
not in sarcomas), as Well as breast tumors. It has also been 
demonstrated that Hpr6 levels are elevated in lung cancer 
tumor cells (Di?lippantonio, et al., Eur. Journal of Cancer 
39: 1936, 2003) and some unpublished data from a microar 
ray analysis shoW that it is elevated in ovarian cancer (L. 
Miller and E. T. Liu, personal communication). Thus, Hpr6 
is Widely overexpressed in non-sarcoma cancer cells. 
Thus, Hpr6 is an excellent target for screening agents that 
enhance the e?cect of anti-cancer agents. In a typical assay 
for compounds or agents that inhibit Hpr6 activity, cells that 
overexpress Hpr6 are exposed to the test agent or compound 
and doxorubicin or other Cyp3A4 metaboliZable anti-cancer 
agent; and test agents or compounds that result in enhanced 
cell death compared to cells that are exposed only to the 
Cyp3A4 metabolizable anti-cancer agent are identi?ed as 
anti-cancer agents. The test compound may be a small 
molecule, peptide, peptoid, monoclonal or polyclonal anti 
body or fragment thereof, an RNA/DNA aptamer, siRNA or 
anti-sense nucleic acid that binds to Hpr6 nucleic acid and 
inactivates it, or the like. 
It is Well knoWn in the art that viability of a cell can be 
determined by contacting the cell With a dye and vieWing it 
under a microscope. Viable cells can be observed to have an 
intact membrane and do not stain, Whereas dying or dead 
cells having “leaky” membranes do stain. Incorporation of 
the dye by the cell indicates the death of the cell. The most 
common dye used in the art for determining viability is 
trypan blue. Viability of cells can also be determined by 
detecting DNA synthesis. Cells can be cultured in cell 
medium With labeled nucleotides (e.g., 3H thymidine). The 
uptake or incorporation of the labeled nucleotides indicates 
DNA synthesis and cell viability. In addition, colonies 
formed by cells cultured in medium indicate cell groWth and 
is another means to test viability of the cells. 
Identi?cation and/ or observation of cells undergoing apo 
ptosis can be another method of determining cell viability. 
Apoptosis is a speci?c mode of cell death recogniZed by a 
characteristic pattern of morphological, biochemical, and 
molecular changes. Cells going through apoptosis appear 
shrunken, and rounded; they also can be observed to become 
detached from culture dish. Thermophological changes 
involve a characteristic pattern of condensation of chromatin 
and cytoplasm Which can be readily identi?ed by micros 
copy. When stained With a DNA-binding dye, such as 
H33258, apoptotic cells display classic condensed and punc 
tate nuclei instead of homogeneous and round nuclei. 
The hallmark of apoptosis is the endonucleolysis, a 
molecular change in Which nuclear DNA is initially 
degraded at the linker sections of nucleosomes to give rise 
to fragments equivalent to single and multiple nucleosomes. 
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When these DNA fragments are subjected to gel electro 
phoresis, they reveal a series of DNA bands Which are 
positioned approximately equally distant from each other on 
the gel. The siZe difference betWeen the tWo bands next to 
each other is about the length of one nucleosome (i.e., 20 
base pairs). This characteristic display of the DNA bands is 
called a DNA ladder and it indicates apoptosis of the cell. 
Apoptotic cells can be identi?ed by How cytometric methods 
based on measurement of cellular DNA content, increased 
sensitivity of DNA to denaturation, or altered light scattering 
properties. These methods are Well knoWn in the art and are 
Within the contemplation of the invention. 
As used herein, “compound” refers to any agent, chemical 
substance, or substrate, Whether organic or inorganic, or any 
protein including antibodies and functional fragments 
thereof, peptides, polypeptides, peptoids, and the like. 
Agents that inactivate Hpr6 also include mutants of Hpr6 
that interfere With Wild-type Hpr6 activity When adminis 
tered to cells. For example, Hpr6-mut, and other mutants of 
Hpr6 that cannot bind heme are useful anti-cancer agents. 
Such mutants include those that have mutations, such as 
point mutations, deletions or additions, for example, to the 
heme binding site of the protein, Which is shoWn in FIG. 7. 
As used herein, the term “antibody” refers to an immu 
noglobulin molecule With a speci?c amino acid sequence 
evoked by an antigen, e.g. Hpr6 or the heme binding region 
of Hpr6, and characterized by reacting speci?cally With the 
antigen in some demonstrable Way. The term “antibody” 
encompasses polyclonal and monoclonal antibody prepara 
tions, CDR-grafted antibody preparations, as Well as prepa 
rations including hybrid antibodies, altered antibodies, 
F(AB)'.sub.2 fragments, F(AB) molecules, Fv fragments, 
single domain antibodies, chimeric antibodies and func 
tional fragments thereof Which exhibit immunological bind 
ing properties of the parent antibody molecule. The anti 
bodies can also be humanized. 
The term “monoclonal antibody” is not limited to anti 
bodies produced through hybridoma technology. The term 
“monoclonal antibody” refers to an antibody or functional 
fragment thereof that is derived from a single clone, includ 
ing any eukaryotic, prokaryotic, or phage clone, and not the 
method by Which it is produced. 
Test agents that are identi?ed as anti-cancer agents (re 
ferred to herein as anti-Hpr6 agents) can be used to treat 
non-sarcoma tumors. Therapeutic treatment of non-sarcoma 
tumors comprises administration of an effective amount of 
the anti-Hpr-6 agent and a Cyp3A4 metaboliZable anti 
cancer agent to a patient. In a preferred embodiment, the 
anti-cancer agent is doxorubicin, although other Cyp3A4 
metaboliZable anti-cancer agents or combinations of agents 
may be used. In one embodiment of this aspect of the 
invention the anti-Hpr6 agent is a mutant form of the Hrp6 
gene, such as Hprt6-mut, Which interferes With the ability of 
Wild-type Hpr6 to protect cells from the effects of Cyp3A4 
mataboliZable anti-cancer agents. The skilled practitioner 
can determine the effective amount of anti-Hpr6 agent 
required to induce such interference. 
The anti-Hpr6 agent and anti-cancer agent may be admin 
istered simultaneously, or Within a short time of one another, 
e.g., about one to 24 hours. In the latter case it is preferred 
that the anti-Hpr6 agent is administered ?rst, but the order 
of administration is not essential. Preferably, the anti-Hpr6 
agent is administered by direct injection into a tumor to be 
treated. HoWever, systemic administration is also possible. 
The present invention also provides a vector, preferably a 
plasmid or an adenoviral vector, Which encodes Hpr6-mut or 
other mutant of Hpr6 that enhances the sensitivity of a tumor 
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cell that overexpresses Hpr6 to Cyp3A4 metaboliZable drugs 
When expressed therein. In a most preferred embodiment, 
the vector is a replication-de?cient adenoviral vector. The 
vector may encode, for example, a mutant of Hpr6 that has 
a mutation in the heme binding region of the gene or a 
fragment of Hrp6 that interferes With the ability of Wild-type 
Hpr6 to protect cells from the effects of Cyp3A4 matabo 
liZable anti-cancer agents, e.g., etoposide, doxorubicin, 
taxol, paclitaxol and camptothecin When expressed in the 
cells. 
The present invention also provides kits for the treatment 
of non-sarcoma tumors comprising at least one Cyp3A4 
metaboliZable anti-cancer agent and at least one anti-Hpr6 
agent. The anti-cancer agent may be for example, doxorubo 
rubicin, etoposide, camptothecin, and combinations thereof. 
The anti-Hrp6 agent is any agent or combination of agents 
that interfere With the ability of Wild-type Hpr6 to protect 
tumor cells from the killing effects of the anti-cancer agent. 
For example, the anti-Hpr6 agent may be an adenoviral 
vector, preferably a replication de?cient adenoviral vector 
encoding Hpr6-mut. 
The folloWing examples are presented for the illustrative 
purposes and it is to be understood that the present invention 
is not limited to those precise embodiments, and that various 
changes and modi?cations can be effected therein by one 
skilled in the art Without departing from the scope and spirit 
of the invention as de?ned by the appended claims. 
EXAMPLE 1 
Generation of a Hrp6 Mutant. Hpr6 Was cloned in tWo 
stages. First, the amino terminal 109 amino acids Were 
ampli?ed from puri?ed MCF-7 cell genomic DNA using the 
primers HPRlFHA (5'-CCCGGGGGATCCGACGCCGC 
CACCATGGAATCCGACTACCCCTATGAT 
GTGCCCGATTACGTCGAGTCCGTCGC 
CGAGGATGTGGTGGCG-3') (SEQ ID N016) and 
HPR330R (5'-CCCATACGGCCCCTCGGGCC-3') (SEQ 
ID N017). The former primer added a single HA epitope tag 
sequence (Asp-Tyr-Pro-Tyr-Asp-Val-Pro-Asp-Tyr-Ala-Glu 
Ser)(SEQ ID N014) to the amino terminus of the Hpr6 open 
reading frame. The ampli?ed DNA Was subcloned into the 
TA cloning vector pCR2.l (InV1trogen; Carlsbad, Calif.), 
then digested With BamHI and KpnI and ligated into the 
plasmid pBK-CMV (Stratagene, LaJolla, Calif.), forming 
the plasmid pRC38. A fragment containing the 3' end of 
Hpr6 Was ampli?ed from the plasmid IMAGE 3254089 
(Research Genetics; Huntsville, Ala.) using the primers 
HPR126F (5'-ACAAGATCGTGCGCGGGGA-3') (SEQ ID 
N018) and HPR690R-APA (5'-TGTGGGCCCCTC 
GAGAAACTTATAGCAAGTGCTC-3') (SEQ ID N019), 
digested With ApaI, and inserted into the ApaI site of the 
plasmid pRC38, forming the plasmid pRC40. The integrity 
of all plasmid insets Was veri?ed by automated sequencing. 
The 3' end of the HPR6 open reading frame containing the 
Dl20G mutation Was ampli?ed from the plasmid IMAGE 
3254089 (Research Genetics, Huntsville, Ala.) using the 
primers HPR-Dl20G-F (5'-TACGGGCCCGAGGGGCCG 
TATGGGGTCTTTGCTGGAAGAGATG 
CATCCAGGGGCCTTGC-3') (SEQ ID N01l0) and HPR 
690R-APA (SEQ ID N09). The resulting PCR product Was 
digested With ApaI and cloned into the same site of the 
plasmid pRC38, Which included the 5' end of the HPR6 open 
reading frame. The resulting plasmid, pRC42, contained the 
full-length HPR6 open reading frame With the Dl20G 
mutation. The HPR6-D120G open reading frame Was 
excised by digestion With BamHI and XhoI and cloned into 
US 7,342,100 B2 
the BglII and XhoI sites of pShuttle-CMV (provided by the 
University of North Carolina at Chapel Hill Adenoviral Core 
Facility), resulting in the plasmid pRC45. 
EXAMPLE 2 
Expression plasmids and viral preparation. The 3' end of 
the HPR6 open reading frame containing the DI20G muta 
tion Was ampli?ed from the plasmid IMAGE 3254089 
(Research Genetics, Huntsville, Ala.) using the primers 
HPR-DI20G-F and HPR-690R-APA (primer sequences 
available on request). The resulting PCR product Was 
digested With ApaI and cloned into the same site of the 
plasmid pRC38 (Hand et al. Journal of Cellular Biochem 
istry 2003; 90: 534-47.), Which included the 5' end of the 
HPR6 open reading frame. The resulting plasmid, pRC42, 
contained the full-length HPR6 open reading frame With the 
D 120G mutation. The HPR6-DI20G open reading frame 
Was excised by digestion With BamHI and XhoI and cloned 
into the BglII and XhoI sites of pShuttle-CMV (provided by 
the University of North Carolina at Chapel Hill Adenoviral 
Core Facility), resulting in the plasmid pRC45. 
Fusion protein plasmids, preparation, and analysis. Hpr6 
GST fusion proteins contained amino acids 43-195 of the 
Hpr6 open reading frame. Hpr6 Was ampli?ed using the 
primers HPR+126F-Bam and HPR+566R-Xho With the 
plasmid pRC40 as a template. PCR products Were cloned 
into the pCR2.1 plasmid (InV1trogen, Carlsbad, Calif.) form 
ing the plasmid pRC44. The Hpr6 fragment Was then ligated 
into the Barn HI and Xho I on the plasmid pGEX-4T-I 
(Amersham Biosciences, PiscataWay, N.J.), forming the 
plasmid pRC46. To introduce the DI20G mutant, the plas 
mid pRC46 Was digested With Apa I and Xho I and ligated 
to the 260 bp Apa I-Xho I fragment of the plasmid pRC45, 
forming the plasmid pGC4. The structure of all of these 
plasmids Was veri?ed by automated sequencing. 
Fusion protein expression Was induced With 1 mM IPTG 
(Fisher) and cells Were lysed in the B-PER reagent (Pierce, 
Rockford, Ill.) and bound to glutathione-agarose beads 
(Pierce). At this stage, the GST-Hpr6-bound columns Were 
visibly broWn due to bound heme, While the GST-Hpr6 
DI20G-bound columns Were White due to the inability of 
this mutant to bind heme. After estimating protein quantity 
by SDS-PAGE electrophoresis, 100/-1 g of Hpr6 or Hpr6 
DI20G proteins Were liberated by digestion With I U of 
thrombin for tWo hours, and absorbance at 400 nm Was 
determined using a Spectronics Genesys 5 spectrophotom 
eter (Spectronics Instruments, Rochester, N.Y.). 
EXAMPLE 3 
Hpr6 binds to heme, and the D120G mutation in the 
heme-1 domain blocks heme-binding activity. Hpr6 is 
highly conserved With a group of proteins that share the 
sequence FYGP-x-GPY-x-x FAG-x-DASR-x-LA (SEQ ID 
NO: 5). AnAsp-to-Gly mutation in this sequence inactivates 
the yeast Dap1p protein (R. Craven, unpublished observa 
tions). An analogous D120G mutation Was made in Hpr6 
and puri?ed the Hpr6 and Hpr6-D120G proteins (FIG. 2A), 
then tested the proteins for heme binding (FIG. 2B). Hpr6 
bound ef?ciently to heme based on absorbance at 400 nm 
(FIG. 2B, left column), and this activity Was absent in the 
Hpr6-D120G protein (FIG. 2B, right column). The measure 
ment Was performed in triplicate, and the difference betWeen 
Hpr6 and Hpr6-D120G absorbance Was statistically signi? 
cant (P:0.03). The absorption curve for Hpr6 shifted from 
400 nm to 420 nm When the protein Was treated With sodium 
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hydrosul?te, as expected (data not shoWn). We conclude that 
Hpr6 is a heme-binding protein, and that Hpr6-D120G is an 
inactive form of the protein. 
EXAMPLE 4 
The Ad-Hpr6-mut adenovirus ef?ciently directs expres 
sion of Hpr6-D120G. An adenovirus (called Ad-Hpr6-mut) 
encoding the inactive Hpr6 protein Was prepared. MDA 
MB-231 human breast cancer cells Were infected With the 
Ad-Hpr6-mut adenovirus, resulting in ef?cient expression of 
the Hpr6-mut protein (FIG. 2C, top panel, lanes 1-3). 
Expression Was dependent on the dose of the virus (FIG. 2C, 
top panel, lanes 1-3), While infection of MDA-MB-231 cells 
With a control Ad-LacZ adenovirus did not yield any detect 
able protein expression (FIG. 2C, top panel, lane 4). At a 
dose of 1000 pfu/cell of Ad-Hpr6-mut, Hpr6-mut Was over 
expressed relative to the endogenous Hpr6 protein (FIG. 2D, 
middle panel, indicated as “Hpr6-mut” and “Hpr6”, respec 
tively). The identity of the Hpr6-mut protein Was con?rmed 
by Western blotting With an antibody to the HA epitope tag 
(FIG. 2D, upper panel, lane 2). We conclude that Hpr6-mut 
is an inactive form of Hpr6, and that overexpression of 
Hpr6-mut is capable of acting as a dominant-negative form 
of the protein. 
EXAMPLE 5 
Drug treatment, viability assays, and immunological 
analyses. Doxorubicin (Sigma, St. Louis, Mo.) Was added to 
culture media and incubated for ?ve days. Cells Were 
incubated With hydrogen peroxide (Fisher), mechlore 
thamine (kindly provided by Dr. Robert OrloWski, Univer 
sity of North Carolina at Chapel Hill) or camptothecin 
(Sigma) for 72 hours. Trypan blue and MTT assays Were 
performed using standard techniques as previously 
described (Hand et al. Journal of Cellular Biochemistry 
2003; 90: 534-47). Western blots of cultured cells and 
tumors Were performed as described previously (Hand et al. 
Journal of Cellular Biochemistry 2003; 90: 534-47; Yang et 
al. Tumor Biology 2003; 24: 61-9). The antibodies used Were 
as folloWs: anti-HA (HAll, BAbCo, Berkeley, Calif.), tubu 
lin (Fisher), and Hpr6 (Meyer et al. Steroids 1998; 63: 
111-6). Cells Were visualiZed using a VistaVision inverted 
microscope attached to a Sony DCS F717 digital camera 
(V WR, Batavia, Ill.). For immuno?uorescence, MCF-7/ 
vector and MCF-7/Hpr6 cells (Hand et al. Journal of Cel 
lular Biochemistry 2003; 90: 534-47) Were ?xed With 3.7% 
formaldehyde, permeabiliZed With 0.1% Triton X-100, 
blocked With 10% normal goat serum, and incubated With 
the HAll monoclonal antibody. Cells Were then Washed, 
incubated With a FITC-Iabeled anti-mouse secondary anti 
body (Santa CruZ Biotechnology, Santa CruZ, Calif.), 
Washed, mounted, and visualiZed using a Zeiss ?uorescent 
microscope. 
Ad-Hpr6-mut synergiZes With doxorubicin in MDA-MB 
231 breast cancer cells. The effect of the Ad-Hpr6-mut 
adenovirus in response to chemotherapy Was analyZed for 
tWo reasons. First, the budding yeast homologue of Hpr6 
controls resistance to damaging agents. Second, We found 
that Hpr6 expression is induced in response to the chemo 
therapeutic drugs doxorubicin and camptothecin in the 
breast cancer cell line MDA-MB-231 (FIG. 1B), as Well as 
in MCF-7 cells (data not shoWn). In contrast to these 
?ndings, Hpr6 expression Was not induced in response to the 
chemotherapeutic drugs cisplatinum and mechlorethamine 
or folloWing treatment With hydrogen peroxide (data not 
shoWn). 
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Ad-Hpr6-mut infection triggered cell death in MDA-MB 
231 cells following doxorubicin treatment (FIG. 3). Doxo 
rubicin treatment caused signi?cantly greater lethality in 
Ad-Hpr6-mut-infected cells (FIG. 3A-D, dashed lines) com 
pared to cells infected With a control Ad-LacZ adenovirus 
(FIG. 3A-D, solid lines), and loss of viability increased 
proportionally With doxorubicin dose (FIG. 3A). Loss of 
viability Was highly signi?cant at a dose of 0.5 (100% 
viability for Ad-LacZ compared to 81% for Ad-Hpr6-mut, 
P:0.0003), 1 (Ad-LacZ, 69% compared to Ad-Hpr6-mut, 
7%; P:0.0002), and 1.5 uM doxorubicin (Ad-LacZ, 29% 
viability compared to 0% for Ad-Hpr6-mut; P:0.008). In the 
absence of doxorubicin, the Ad-Hpr6-mut adenovirus had no 
detectable effect on tumor cell survival or proliferation (FIG. 
3A-C, 0 dose of doxorubicin). Viability Was also measured 
by trypan blue assay, and as expected, Ad-Hpr6-mut-in 
fected cells Were more sensitive to doxorubicin than Ad 
LacZ-infected cells (FIG. 3B, 1 uM dose of doxorubicin, 
P:0.0006). 
Doxorubicin-mediated cell death Was dependent on the 
dose of the Ad-Hpr6-mut adenovirus (FIG. 3C). At a ?xed 
dose of 1 uM doxorubicin, increased concentrations of the 
Ad-Hpr6-mut adenovirus increased cell death. There Was no 
signi?cant loss ofviability at a dose of 500 pfu/cell, but loss 
of viability Was highly signi?cant at a dose of 1000 (70% 
viability for Ad-LacZ compared to 7% for Ad-Hpr6-mut, 
P:0.0002), and 2000 (50% viability for Ad-LacZ compared 
to 2% for Ad-Hpr6-mut, P:0.0001) pfu/cell Ad-Hpr6-mut. 
Thus, Hpr6 is a mediator of resistance to doxorubicin in 
MDA-MB-231 breast cancer cells. 
A number of chemotherapeutic drugs target topoi 
somerases. The ability of Ad-Hpr6-mut to regulate survival 
folloWing treatment With the drugs etoposide and camptoth 
ecin Was tested. MDA-MB-231 cells Were infected With 
Ad-LacZ or Ad-Hpr6-mut and treated With 125-1000 nM 
camptothecin, a topoisomerase I inhibitor. Synergism 
betWeen Ad-Hpr6-mut and camptothecin Was signi?cant at 
125 nM (FIG. 3D, 79%:9 for Ad-LacZ vs. 48%:2 for 
Ad-Hpr6-mut, P:0.005). We also detected a less dramatic 
but signi?cant synergism betWeen Ad-Hpr6-mut and etopo 
side. Ad-Hpr6-mut caused a signi?cant increase in cell death 
at doses of 10 uM etoposide (27%:08 for Ad-LacZ vs. 
20%:2 for Ad-Hpr6-mut, P:0.009). Thus, Hpr6-mut sensi 
tiZes breast cancer cells to multiple topoisomerase inhibi 
tors. 
Doxorubicin frequently induces cell death via the apop 
totic pathWay. We detected rounded cells in MDA-MB-231 
cells infected With Ad-Hpr6-mut and treated With doxoru 
bicin, although the majority of the cells had a Wasted, 
necrotic morphology (FIG. 4A, right panel). These cells 
Were less evident in cells infected With a control adenovirus 
(FIG. 4A, left panel). In spite of the fact the cells Were 
rounded, We Were unable to detect classical markers of 
apoptosis, including cleavage of PARP, the focal adhesion 
kinase (F AK), endonucleolytic cleavage of chromosomal 
DNA, or nuclear condensation. We conclude that Hpr6-mut 
infection induces necrotic cell death in cells treated With 
doxorubicin. 
EXAMPLE 6 
Ad-Hpr6-mut infection does not cause cell death from 
peroxide or other chemotherapeutic drugs. Doxorubicin 
causes toxicity through the creation of reactive oxygen 
species and by inhibiting topoisomerase activity. We tested 
Whether Ad-Hpr6-mut infection altered the response of 
MDA-MB-231 cells to oxidative damage. Cells treated With 
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25-100 uM hydrogen peroxide for 72 hours died to the same 
extent When infected With Ad-LacZ or Ad-Hpr6-mut (data 
not shoWn). We also tested the extent to Which Ad-Hpr6-mut 
sensitiZed MDA-MB-23 I cells to additional chemothera 
peutic drugs. MDA-MB-231 cells Were infected With Ad 
LacZ or Ad-Hpr6-mut and treated With the alkylating agent 
mechlorethamine, and Hpr6 -mut expression had no effect on 
viability, (data not shoWn). Similar results Were obtained 
With cisplatinum (data not shoWn). We conclude that the 
effects of Ad-Hpr6-mut are relatively speci?c and do not 
include all classes of damaging agents and drugs. 
Because doxorubicin induces resistance through activa 
tion of multidrug transporters, it Was believed possible that 
Hpr6 could act as a membrane-associated drug transport 
protein. To test this possibility, We infected MDA-MB-231 
cells With Ad-LacZ or Ad-Hpr6-mut, then treated them With 
doxorubicin and examined doxorubicin accumulation by 
?uorescent microscopy 2 hours later. This approach has been 
previously used to examine the effect of P-glycoprotein on 
doxorubicin accumulation in breast cancer cells (Wu H et al. 
Cancer Research 2003; 63: 1515-9). The cellular morpholo 
gies of Ad-LacZ- and Ad-Hpr6-mut-infected cells Were 
similar (FIG. 4B, upper panels), no difference in doxorubicin 
accumulation in Ad-LacZ vs. Ad-Hpr6-mut-infected cells 
Was detected (FIG. 4B, bottom panels). Doxorubicin con 
centrations Were also measured after 24 hours of treatment 
by ?uorescence-activated cell sorting (F ACS) and no dif 
ferences in doxorubicin levels Were detected (data not 
shoWn). This result Was consistent With the ?nding that 
Ad-Hpr6-mut does not synergiZe With mechlorethamine, 
because membrane drug transporters usually act on multiple 
drugs. In addition, We subsequently found that Hpr6 does 
not localiZe to the cell membrane (see Example 7). Thus, 
Hpr6 is unlikely to function as a membrane-associated multi 
drug transport protein. 
EXAMPLE 7 
Hpr6 is over-expressed in breast tumors. 
Cell lines, culturing, and infection. MDA-MB-23 Ihuman 
breast cancer cells Were a kind gift from Dr. Carolyn Sartor 
(University of North Carolina at Chapel Hill) and Were 
maintained in Dulbecco’s Modi?ed Eagle Medium With 
10% Serum Supreme (Fisher, Chicago, Ill.) and penicillin 
and streptomycin at 370 C. in 5% CO2 in air. MCF-7 cells 
engineered to over-express Hpr6 have been described pre 
viously (Hand et al. Journal of Cellular Biochemistry 2003; 
90: 534-47, incorporated herein in its entirety), and MCF-7 
cells Were maintained in Minimal Essential Medium con 
taining 10% fetal bovine serum and antibiotics. 
Because of the role of Hpr6 in chemotherapeutic resis 
tance, the expression of Hpr6 in clinical breast tumor 
samples Was analyZed. Hpr6 expression Was determined in 
pairs of non-malignant breast tissue and adjacent breast 
tumors from the same patients. Hpr6 Was expressed Weakly 
in 9 separate non-malignant breast tissue samples (3 are 
shoWn in FIG. 5A, lanes 1, 3, and 5) and Was over-expressed 
in tumors from 7 of these patients (FIG. 5A, examples in 
lanes 2 and 6). Hpr6 over-expression in tumors ranged from 
strong (FIG. 5A, lane 2) to moderate (FIG. 5A, lane 6), and 
Hpr6 Was not over-expressed in some tumors (FIG. 5A, lane 
4). Hpr6 Was also highly expressed in 4/11 non-matched 
breast tumor samples (FIG. 5B). Taking all of the samples 
together, it Was found that Hpr6 Was highly expressed in 
6/ 18 breast tumors and Was moderately expressed in 5/ 18 
tumors (FIG. 5C, right). LoW expression levels ere found in 
6/ 18 breast tumors, and a single tumor had no detectable 
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expression of Hpr6 (FIG. 5C, right). In all cases, non 
malignant breast tissues exhibited Weak but detectable 
expression of Hpr6 (FIG. 5C, left). Thus, Hpr6 is over 
expressed in breast cancer. 
The sub-cellular localization of Hpr6 Was determined. 
The antibody used for Western blotting Was raised to a 
peptide sequence at the Hpr6 amino terminus, and no 
staining Was detected With this antibody (data not shoWn). 
MCF-7 breast cancer cells expressing an epitope-tagged 
14 
Hpr6 Were stained With a monoclonal antibody to the 
epitope tag by immuno?uorescence. No staining Was detect 
able in MCF-7 cells harboring a control plasmid (FIG. 6, 
panel 2), While the majority of MCF-7/Hpr6 cells exhibited 
sharp perinuclear staining (FIG. 6, panels 4 and 6). This 
perinuclear staining resembled that of the endoplasmic 
reticulum dye BODIPY Brefeldin A (Hand and Craven, 
unpublished observations), suggesting that Hpr6 localiZes to 
the endoplasmic reticulum. 
SEQUENCE LISTING 
<160> NUMBER OF SEQ ID NOS : 1O 
<211> LENGTH: 195 
<2l3> ORGANISM: Homo sapiens 
<400> SEQUENCE: 1 
Met Ala Ala Glu Asp Val Val Ala Thr Gly Ala Asp Pro 
1 5 1O 
Glu Ser Gly Gly Leu Leu His Glu Ile Phe Thr Ser Pro 
20 25 
Leu Leu Leu Gly Leu Cys Ile Phe Leu Leu Tyr Lys Ile 
35 4O 45 
Asp Gln Pro Ala Ala Ser Gly Asp Ser Asp Asp Asp Glu 
50 55 6O 
Leu Pro Arg Leu Lys Arg Arg Asp Phe Thr Pro Ala Glu 
Phe Asp Gly Val Gln Asp Pro Arg Ile Leu Met Ala Ile 
85 90 
Val Phe Asp Val Thr Lys Gly Arg Lys Phe Tyr Gly Pro 
100 105 
Tyr Gly Val Phe Ala Gly Arg Asp Ala Ser Arg Gly Leu 
115 120 125 
Cys Leu Asp Lys Glu Ala Leu Lys Asp Glu Tyr Asp Asp 
130 135 140 
Leu Thr Ala Ala Gln Gln Glu Thr Leu Ser Asp Trp Glu 
145 150 155 
Thr Phe Lys Tyr His His Val Gly Lys Leu Leu Lys Glu 
165 170 
Pro Thr Val Tyr Ser Asp Glu Glu Glu Pro Lys Asp Glu 
180 185 
Lys Asn Asp 
195 
<211> LENGTH: 619 
<2l3> ORGANISM: Homo sapiens 
<400> SEQUENCE: 2 
Ser Asp Leu 
15 
Leu Asn Leu 
30 
Val Arg Gly 
Pro Pro Pro 
Leu Arg Arg 
80 
Asn Gly Lys 
Glu Gly Pro 
110 
Ala Thr Phe 
Leu Ser Asp 
Ser Gln Phe 
160 
Gly Glu Glu 
Ser Ala Arg 
190 
atggctgccg aggatgtggt ggcgactggc gccgacccaa gcgatctgga gagcggcggg 6O 
ctgctgcatg agattttcac gtcgccgctc aacctgctgc tgcttggcct ctgcatcttc 120 
ctgctctaca agatcgtgcg cggggaccag ccggcggcca gcggcgacag cgacgacgac 180 
gagccgcccc ctctgccccg cctcaagcgg cgcgacttca cccccgccga gctgcggcgc 240 
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—cont inued 
18 
Phe Tyr Gly Pro Xaa Gly Pro Tyr Xaa Xaa Phe Ala Gly Xaa Asp Ala 
l 
Ser Arg Xaa Leu Ala 
cccgggggat ccgacgccgc caccatggaa tccgactacc cctatgatgt 
SEQ ID NO 6 
LENGTH: 90 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Chemically Synthesized 
SEQUENCE: 6 
gtcgagtccg tcgccgagga tgtggtggcg 
SEQ ID NO '7 
LENGTH: 20 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Chemically Synthesized 
SEQUENCE: '7 
cccatacggc ccctcgggcc 
SEQ ID NO 8 
LENGTH: 19 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Chemically Synthesized 
SEQUENCE: 8 
acaagatcgt gcgcgggga 
SEQ ID NO 9 
LENGTH: 34 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Chemically Synthesized 
SEQUENCE: 9 
tgtgggcccc tcgagaaact tatagcaagt gctc 
SEQ ID NO 10 
LENGTH: 59 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Chemically Synthesized 
SEQUENCE: l0 
gcccgattac 
tacgggcccg aggggccgta tggggtcttt gctggaagag atgcatccag gggccttgc 
9O 
19 
34 
59 
What is claimed is: 
1. An isolated polypeptide having the amino acid 
sequence of SEQ ID NOzll. 
